durvalumab

an IgG1 that targets programmed cell death 1 ligand 1 (PD-L1); enhances the immune response to tumor cells and is used for the treatment of locally advanced or metastatic urothelial carcinoma

Also Known As:

Networked: 910 relevant articles (132 outcomes, 348 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Antonia, Scott J: 14 articles (01/2022 - 01/2017)
2.	Dennis, Phillip A: 14 articles (11/2021 - 11/2017)
3.	Özgüroğlu, Mustafa: 13 articles (06/2022 - 11/2017)
4.	Paz-Ares, Luis: 11 articles (06/2022 - 11/2017)
5.	Gupta, Ashok: 11 articles (11/2021 - 03/2016)
6.	Planchard, David: 10 articles (01/2022 - 01/2016)
7.	Reck, Martin: 10 articles (01/2022 - 04/2016)
8.	Rimner, Andreas: 10 articles (01/2022 - 01/2020)
9.	Chaft, Jamie E: 9 articles (01/2022 - 03/2016)
10.	Gray, Jhanelle E: 9 articles (01/2022 - 11/2017)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2020 - "Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). " 12/01/2019 - "In the ongoing, phase 3 PACIFIC trial, durvalumab improved the primary endpoints of progression-free survival and overall survival compared with that for placebo, with similar safety, in patients with unresectable, stage III non-small-cell lung cancer. " 01/01/2023 - "Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? " 12/01/2023 - "Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer." 01/01/2023 - "Durvalumab following chemoradiation in unresectable stage III non-small cell lung cancer (NSCLC) has led to improved outcomes. "
2.	Neoplasms (Cancer) 05/01/2019 - "Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors." 01/01/2023 - "This study aims to develop a population TK model in combination with a parametric survival model by sequential and joint modeling approaches to characterize durvalumab phase I/II data from patients with metastatic urothelial cancer, and to evaluate and compare the performance of the two modeling approaches in terms of parameter estimates, TK and survival predictions, and covariate identification. " 05/01/2022 - "KEYNOTE-045, IMvigor211, CheckMate275, Javelin Solid Tumor, MEDI4736, and KEYNOTE-0528 clinical trials. " 01/01/2022 - "The proposed framework successfully describes tumor volume trajectories observed in early-stage clinical trials of durvalumab monotherapy in patients with HCC. " 07/01/2021 - "The purpose of our study was to evaluate the association between the degree of tumor PD-L1 expression and outcomes of stage III NSCLC patients treated with durvalumab. "
3.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2021 - "The present study reports a case of durvalumab-induced demyelinating lesions in a patient with extensive-stage small-cell lung cancer. " 01/01/2023 - "Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report." 01/01/2021 - "This report describes a 66-year-old female who received Durvalumab for metastatic small-cell lung cancer. " 01/01/2021 - "Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report." 12/01/2020 - "[New European approvals: Durvalumab - In first line metastatic small-cell lung cancer]."
4.	Carcinoma (Carcinomatosis) 11/20/2023 - "Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17." 01/01/2022 - "Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma." 01/01/2020 - "Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). " 01/01/2018 - "Re: Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study." 09/14/2017 - "Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study."
5.	Squamous Cell Carcinoma of Head and Neck 01/01/2019 - "Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort." 01/01/2023 - "Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC." 11/01/2022 - "A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC." 01/01/2022 - "Using pooled data from the phase II HAWK and CONDOR studies, we investigated the association of baseline PD-L1 expression with durvalumab efficacy in patients with R/M HNSCC. " 01/01/2019 - "Durvalumab safety in HNSCC was manageable and consistent with other cohorts of the study. "

Related Drugs and Biologics

1.	tremelimumab
2.	atezolizumab
3.	Cisplatin (Platino)
4.	Immune Checkpoint Inhibitors
5.	Platinum
6.	Etoposide (VP 16)
7.	Nivolumab
8.	pembrolizumab
9.	Monoclonal Antibodies
10.	B7-H1 Antigen

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Chemoradiotherapy
4.	Immunotherapy
5.	Radiotherapy